United States: Capitol Hill Healthcare Update

Delayed Senate Health Vote Boon to GOP or Just Prolonging the Inevitable?

Senate Majority Leader Mitch McConnell's announcement that he would delay a key procedural vote scheduled for this week on the Republicans' healthcare overhaul gave the GOP yet more time to find a legislative solution that can pass the Senate.

But given McConnell's inability so far to cobble together a majority to repeal the Affordable Care Act, the delay may just be prolonging what's turning into a political nightmare for the GOP. Despite congressional majorities in the House and Senate, Republicans can't rally around a plan to overturn a law they have campaigned against for seven years.

McConnell was forced to push back a vote on whether to begin debating the GOP health bill, the Better Care Reconciliation Act, after Sen. John McCain underwent surgery for a blood clot Saturday. McCain won't be back in Washington for at least another week. 

McConnell needs McCain's vote on the so-called "motion to proceed." Of the 52 Senate Republicans, two have already said they would oppose that motion. One more GOP "no" vote or a Republican not voting, and the party's bill would effectively die before it could even be debated or voted on.

Sens. Rand Paul (R-Ky.) and Susan Collins (R-Maine) have said they would vote to block consideration of the Republicans' health bill.

McConnell had earlier announced the Senate would remain in session for the first two weeks of August, rather than adjourning as planned on July 28 for a recess that would last until after Labor Day. Some Republican staff were hopeful the delay in considering the health bill and the shortened August recess could give McConnell additional time to craft a political solution that has so far eluded the renowned legislative dealmaker.

But others were openly pessimistic, lamenting the political consequences of failing to address a law Republicans have told their voters they would repeal as well as the opportunity cost of the legislative time lost during the debate on the ACA.

McConnell's challenge remains balancing the demands of conservatives who want to wipe out as much of the ACA as possible and those of more moderate Republicans who want to protect states that have expanded their Medicaid programs and Americans whose insurance covers pre-existing conditions.

Senate Health Bill Delay May Spur Action on User Fee Renewal

The House last week approved by voice vote a five-year renewal of FDA user fees for pharmaceutical and medical technology manufacturers, potentially setting up action in the Senate for later this month.

With Senate votes delayed on Republicans' plans to repeal the Affordable Care Act, the user fee reauthorization could see accelerated floor time in the Senate. Senate leaders as of Monday had not announced a timetable for considering the House-passed legislation.

Although the user fee bill is largely non-controversial, Senate leaders had hoped to approve it after voting on the ACA bill. GOP leaders feared the user fee package could become collateral partisan damage from the ACA debate.

During the past several weeks, key House and Senate staff worked to pre-negotiate several policy issues to allow the House and Senate to vote on a single bill rather than establishing a formal conference committee between the two chambers. The latter process could have made the bill subject to more procedural hurdles and an attractive political target to which lawmakers could attach controversial provisions, such as on drug pricing.

The user fees for pharmaceutical and medical technology manufacturers expire September 30. Without congressional action by August 1, mandatory notices will be sent to FDA staff whose jobs are tied to user fee funding, warning of potential layoffs if Congress fails to renew the program. Lawmakers in both parties say they want to avoid triggering those notices.

House Hearing This Week on 340B Drug Program

The House Energy and Commerce Subcommittee on Oversight and Investigations will hold a hearing Tuesday on the Health Resources and Services Administration's (HRSA's) oversight of the 340B prescription drug discount program.

This will be the second committee hearing looking into HRSA's management of the program, which has come under bipartisan criticism in recent years. Witnesses include Krista Pedley, director of HRSA's Office of Pharmacy Affairs; Debbie Draper, director of health care at the Government Accountability Office; and Erin Bliss of HHS' inspector general office.

Separately, the Centers for Medicare & Medicaid Services (CMS) proposed last week to reduce the reimbursement rate for Medicare Part B payments to hospitals for drugs covered by the 340B program. The move was designed to reflect the discounted rate hospitals pay for those drugs.

The subcommittee has been critical of what it says is HRSA's lax oversight of the discount program while the program has mushroomed in recent years. The number of 340B covered entities has grown from 3,200 in 2011 to 12,148 as of last October, and the number of hospitals participating in the program has increased from 591 in 2005 to 2,871 as of this month.

Despite the size of the program – entities saved $4.5 billion in drug costs in fiscal 2014 – the GAO and other offices have criticized HRSA for failing to adequately supervise the program, including infrequent audits of participating entities.

Hatch, Grassley Question CMS on Meaningful Use Overpayments

The Department of Health and Human Services' (HHS') inspector general in June announced that CMS had overpaid physicians for electronic health record incentive payments by more than $700 million, and two key senators want to know what the agency is doing about it.

Finance Committee Chairman Orrin Hatch (R-Utah) and Judiciary Committee Chairman Chuck Grassley (R-Iowa) want to know if CMS is "capable of recovering taxpayer money that should not have been spent." In a letter to CMS Administrator Seema Verma, the senators want to know what the agency is doing about the excess payments from 2011 to 2014 and what it is doing to prevent future over-payments.

HHS' inspector general found physicians had failed to demonstrate meaningful use of electronic records, and that CMS made inappropriate incentive payments to doctors who switched between Medicare and Medicaid.

House Panel Approves Medicare Reimbursement for Telehealth

The House Ways and Means Committee last week approved bipartisan legislation that would allow for Medicare to reimburse for monthly telemedicine visits at home for end-stage renal disease patients.

Introduced by committee Chairman Kevin Brady (R-Texas) and the panel's top Democrat, Rep. Richard Neal (D-Mass.), the legislation would make several changes to the home infusion and dialysis benefits under Medicare Part B.

Separately, the committee also approved legislation that would make permanent Medicare Advantage special needs plans for beneficiaries who are institutionalized. Introduced by Health Subcommittee Chairman Pat Tiberi (R-Ohio), the bill would authorize for five years special needs plans for beneficiaries who are dually eligible for Medicare and Medicaid and special needs plans for those with chronic conditions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.